Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Association of Anxiety Symptoms in Offspring of Bipolar Parents with Serotonin Transporter-Linked Polymorphic Region (5-HTTLPR) Genotype.

Park MH, Sanders E, Howe M, Singh M, Hallmayer J, Kim E, Chang K.

J Child Adolesc Psychopharmacol. 2015 Aug;25(6):458-66. doi: 10.1089/cap.2014.0115. Epub 2015 Jul 28.

2.

Involvement of serotonin transporter gene polymorphisms (5-HTT) in impulsive behavior in the japanese population.

Nomura M, Kaneko M, Okuma Y, Nomura J, Kusumi I, Koyama T, Nomura Y.

PLoS One. 2015 Mar 16;10(3):e0119743. doi: 10.1371/journal.pone.0119743. eCollection 2015.

3.

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Fabbri C, Porcelli S, Serretti A.

Can J Psychiatry. 2014 Feb;59(2):62-75. Review.

4.

Molecular actions and clinical pharmacogenetics of lithium therapy.

Can A, Schulze TG, Gould TD.

Pharmacol Biochem Behav. 2014 Aug;123:3-16. doi: 10.1016/j.pbb.2014.02.004. Epub 2014 Feb 15. Review.

5.

Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder.

Sahraian S, Babashams M, Reza-Soltani P, Najmabadi H, Kahrizi K, Gorgani SH.

Iran J Psychiatry. 2013 Jun;8(2):86-91.

6.

SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

Shiroma PR, Drews MS, Geske JR, Mrazek DA.

Am J Geriatr Psychiatry. 2014 Nov;22(11):1140-8. doi: 10.1016/j.jagp.2013.02.012. Epub 2013 Aug 20.

7.

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy.

Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM.

Pharmgenomics Pers Med. 2012;5:19-35. doi: 10.2147/PGPM.S23462. Epub 2012 Jan 13.

8.

Serotonin transporter gene polymorphism and psychiatric disorders: is there a link?

Margoob MA, Mushtaq D.

Indian J Psychiatry. 2011 Oct;53(4):289-99. doi: 10.4103/0019-5545.91901.

9.

The clinical pharmacology of depressive states.

Schulz P, Macher JP.

Dialogues Clin Neurosci. 2002 Mar;4(1):47-56.

10.

Pharmacogenetics of antidepressants.

Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, Serretti A.

Front Pharmacol. 2011 Feb 16;2:6. doi: 10.3389/fphar.2011.00006. eCollection 2011.

11.

International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.

Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gordon E.

Trials. 2011 Jan 5;12:4. doi: 10.1186/1745-6215-12-4.

12.

Pharmacogenetics of antidepressant response.

Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A.

J Psychiatry Neurosci. 2011 Mar;36(2):87-113. doi: 10.1503/jpn.100059. Review.

13.

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.

Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR, Lotrich FK, Rollman BL, Shear MK, Thompson PA, Andreescu C, Pollock BG.

J Clin Psychopharmacol. 2010 Dec;30(6):672-7.

14.

Antidepressant response and the serotonin transporter gene-linked polymorphic region.

Taylor MJ, Sen S, Bhagwagar Z.

Biol Psychiatry. 2010 Sep 15;68(6):536-43. doi: 10.1016/j.biopsych.2010.04.034. Epub 2010 Jul 7. Review.

15.

The association between serotonin transporter gene promotor polymorphism (5-HTTLPR) and elemental mercury exposure on mood and behavior in humans.

Echeverria D, Woods JS, Heyer NJ, Martin MD, Rohlman DS, Farin FM, Li T.

J Toxicol Environ Health A. 2010;73(15):1003-20. doi: 10.1080/15287390903566591.

16.

How possible is the development of an operational psychometric method to assess the presence of the 5-HTTLPR s allele? Equivocal preliminary findings.

Gonda X, Fountoulakis KN, Rihmer Z, Laszik A, Akiskal HS, Bagdy G.

Ann Gen Psychiatry. 2010 May 7;9:21. doi: 10.1186/1744-859X-9-21.

17.

A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.

Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR; HALT-C Trial Group.

Psychosomatics. 2010 Mar-Apr;51(2):137-48. doi: 10.1176/appi.psy.51.2.137.

18.

The promise and reality of pharmacogenetics in psychiatry.

Zandi PP, Judy JT.

Psychiatr Clin North Am. 2010 Mar;33(1):181-224. doi: 10.1016/j.psc.2009.12.001. Review.

19.

SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A.

Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M.

Psychiatr Genet. 2009 Dec;19(6):281-91. doi: 10.1097/YPG.0b013e32832a506e.

20.

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression.

Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Müller-Myhsok B.

Arch Gen Psychiatry. 2009 Sep;66(9):966-75. doi: 10.1001/archgenpsychiatry.2009.95.

Supplemental Content

Support Center